

Date: 31st January, 2022

BSE Ltd.
Corporate Service Department
1st Floor, P.J. Towers,
Dalal Street,
Mumbai 400 001

The National Stock Exchange of India Ltd.
Exchange Plaza, 3rd Floor,
Plot No. C/1, 'G' Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

Scrip ID: KRSNAA
Scrip Code: 543328

Symbol: KRSNAA
Series: EQ

Dear Sir/Madam,

Subject: Unaudited Financial Results Q3FY2021-22

Please find enclosed herewith Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and nine months ended 31st December, 2021 along with Limited Review report thereon.

It is requested to take this intimation on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Nikhil Deshpande
Company Secretary



Encl: As above

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Group pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**The Board of Directors
Krsnaa Diagnostics Limited**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Krsnaa Diagnostics Limited ('the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2021 and the year to-date results for the period from April 01, 2021 to December 31, 2021 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulations'). This statement is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
2. This Statement has been prepared by the Holding Company's Management in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



MSKA & Associates

Chartered Accountants

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the following entities:

Sr. No	Name of the Company	Relationship with the Holding Company
1	KDPL Diagnostics (Amritsar) Private Limited	Wholly Owned Subsidiary
2	KDPL Diagnostics (Bathinda) Private Limited	Wholly Owned Subsidiary
3	KDPL Diagnostics (Jalandhar) Private Limited	Wholly Owned Subsidiary
4	KDPL Diagnostics (Ludhiana) Private Limited	Wholly Owned Subsidiary
5	KDPL Diagnostics (Patiala) Private Limited	Wholly Owned Subsidiary
6	KDPL Diagnostics (SAS Nagar) Private Limited	Wholly Owned Subsidiary
7	Krsnaa Diagnostics (Mohali) Private Limited	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement are prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the interim financial information of Seven subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs. 3.01 million as at December 31, 2021 and total revenue of Rs. 5.32 million and Rs. 5.32 million, total net loss after tax of Rs. 8.98 million and Rs. 9.21 million and total comprehensive loss of Rs. 8.98 million and Rs. 9.21 million for the quarter ended December 31, 2021 and for the period from April 01, 2021 to December 31, 2021 respectively, and cash inflows of Rs. 2.24 million for the period from April 01, 2021 to December 31, 2021, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.



MSKA & Associates

Chartered Accountants

Our conclusion on the Statement is not modified in respect of the above matter.

For MSKA & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Signed by Nitin
Manohar
Jumani
Date:
2022.01.31
15:19:45



Nitin Manohar Jumani
Partner
Membership No.: 111700
UDIN: 22111700AAAAAF5963

Place: Pune
Date: January 31, 2022

Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended		Nine months ended
		December 31, 2021	September 30, 2021	December 31, 2021
		(Unaudited)	(Unaudited)	(Unaudited)
1	Income			
	Revenue from operations	1,064.68	1,082.63	3,472.03
	Other income	43.39	32.30	108.07
	Total Income	1,108.07	1,114.93	3,580.10
2	Expenses			
	Cost of material consumed	117.46	135.88	475.93
	Employee benefits expense	142.59	128.17	394.85
	Finance costs	23.59	82.14	166.94
	Depreciation and amortization expense	106.34	103.32	309.42
	Fees to hospitals and others	274.39	274.13	831.63
	Other expenses	230.17	225.09	735.13
	Total Expenses	894.54	948.73	2,913.90
3	Profit / (loss) before tax (1) - (2)	213.53	166.20	666.20
4	Tax expenses			
	Income Tax charge	44.61	28.93	123.38
	Deferred tax charge/(credit)	5.60	12.01	38.29
	Total tax expenses	50.21	40.94	161.67
5	Profit / (loss) for the period (3) - (4)	163.32	125.26	504.53
6	Other comprehensive income			
	Items that will not be reclassified subsequently to profit and loss	-	-	-
	Re-measurement gains / (losses) on defined benefit plans	(0.09)	(0.10)	(0.29)
	Income tax effect	0.03	0.02	0.07
	Total other comprehensive income/(loss) for the period	(0.06)	(0.08)	(0.22)
7	Total comprehensive Income/(loss) for the period, net of tax (5+6)	163.26	125.18	504.31
	Profit/(loss) for the period/year			
	Attributable to:			
	Equity Holders of the Holding Company	163.32	125.26	504.53
	Non Controlling Interests	-	-	-
		163.32	125.26	504.53
	Total other comprehensive income/(loss) for the period			
	Attributable to:			
	Equity Holders of the Holding Company	(0.06)	(0.08)	(0.22)
	Non Controlling Interests	-	-	-
		(0.06)	(0.08)	(0.22)
	Total comprehensive Income/(loss) for the period			
	Attributable to:			
	Equity Holders of the Holding Company	163.26	125.18	504.32
	Non Controlling Interests	-	-	-
		163.26	125.18	504.32
8	Paid-up equity share capital (Face Value of Rs. 5/- Each)	156.99	156.99	156.99
	Earnings per share - After split (Not annualised for quarter & nine months)			
	Basic (Rs.)	5.67	4.51	17.49
	Diluted (Rs.)	5.64	4.47	17.43

For & on behalf of Board
Krsnaa Diagnostics Limited

P. Bhatevara

Pallavi Bhatevara
Managing Director
DIN: 03600332



Place: Pune
Date: January 31, 2022

Krsnaa Diagnostics Limited
(Formerly known as Krsnaa Diagnostics Private Limited)

Notes to Unaudited Consolidated Financial Results:


1. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of The Holding Company at its meeting held on January 31, 2022.
 2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
 3. The Holding Company is converted from Private Limited Company to Public Limited Company, pursuant to Special Resolution passed in extraordinary general meeting of the shareholders held on April 25, 2021 & consequently the name of The Holding Company has been changed to Krsnaa Diagnostics Limited pursuant to fresh certificate of Incorporation issued by Registrar of Company dated May 6, 2021.
 4. The Holding Company, pursuant to shareholders' resolution dated April 25, 2021, sub-divided its equity share capital by sub-dividing the face value of the Equity Shares from ₹10 to ₹5 per Equity Share. Accordingly, the issued and paid-up capital of our Company was sub-divided from 6,494,964 Equity Shares of ₹10 each to 12,989,928 Equity Shares of ₹5 each.
 5. Pursuant to resolution passed at the meeting of Board of Director's held on July 23, 2021, 1,42,01,600 equity shares were issued to compulsory convertible preference shareholders of series A and series C in the ratio 2:1
 6. The Holding Company has completed Initial Public Offer (IPO) of 1,27,31,605 Equity Shares of the face value of Rs. 5/- each at an issue price of Rs. 954/- per Equity Share to non employee category shareholders and Rs. 861/- per Equity Share to employee category shareholders, comprising offer for sale of 85,25,520 equity shares by selling shareholders and fresh issue of 42,06,085 equity shares. The equity shares of The Holding Company were listed on BSE Limited and National Stock Exchange of India Limited on August 16, 2021.
 7. The Holding Company has invested into seven special purpose vehicles (SPVs) which are wholly owned subsidiaries namely, - KDPL Diagnostics (Ludhiana) Private Limited on March 22, 2021, KDPL Diagnostics (Amritsar) Private Limited on March 24, 2021, KDPL Diagnostics (Bathinda) Private Limited on March 24, 2021, KDPL Diagnostics (Jalandhar) Private Limited on March 24, 2021, KDPL Diagnostics (Patiala) Private Limited on March 25, 2021, KDPL Diagnostics (SAS Nagar) Private Limited on March 25, 2021 and Krsnaa Diagnostics (Mohali) Private Limited on July 27, 2021
- The Holding Company has remitted the amount towards subscription of share capital in these SPVs on April 12, 2021 & August 21, 2021. In the absence of the necessary agreement being executed and transfer of funds for subscription of share capital of these subsidiaries by March 31, 2021 The Holding Company has not consolidated the SPVs in its financial statement for the year ended March 31, 2021.
8. The Group's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, Tele- Reporting Services, and all type of Blood and Urine Investigation. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence no separate segment information has been furnished herewith.
 9. The management has made an assessment of the impact of COVID-19 on the Group operations, financial performance and position as at and for the quarter & nine months ended December 31, 2021 and has concluded that the impact is primarily on the operational aspects of the business. In making the assessment management has considered the recoverability of trade receivables, investment and other assets and also considered the external and internal information available up to the date of approval of these financial results including status of existing and future customer orders, cash flow projections etc. and concluded that there is no significant impact which is required to be recognized in the financial results. Accordingly, no adjustments have been made to the financial results.
 10. Previous period figures have been regrouped/ rearranged wherever considered necessary.

For & on behalf of Board
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: January 31, 2022



Independent Auditor's Review Report on unaudited quarterly and year to date standalone financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**The Board of Directors
Krsnaa Diagnostics Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krsnaa Diagnostics Limited ('the Company') for the quarter ended December 31, 2021 and the year to-date results for the period April 01, 2021 to December 31, 2021 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation'). Attention is drawn to the fact that the figures for the corresponding quarter ended December 31, 2020 as reported in these standalone financial results have been approved by the Company's Board of Directors, but have not been subjected to review. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
2. This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether standalone financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Signed by Nitin
Manohar
Jumani
Date:
2022.01.31
15:18:37



Nitin Manohar Jumani
Partner
Membership No.:111700
UDIN: 22111700AAAAAE9570


Place: Pune
Date: January 31, 2022

Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2021

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year Ended
		December 31, 2021	September 30, 2021	December 31, 2020	December 31, 2021	December 31, 2020	March 31, 2021
		(Unaudited)	(Unaudited)	(Unaudited / Unreviewed - Refer Note 6)	(Unaudited)	Audited - (Refer Note 6)	Audited
1	Income						
	Revenue from operations	1,063.11	1,082.63	978.50	3,470.46	3,005.44	3,964.56
	Gain on fair value movement of Compulsory Convertible Preference Share	-	-	-	-	2,527.84	2,527.84
	Other income	43.39	32.30	28.42	108.07	93.73	122.36
	Total Income	1,106.50	1,114.93	1,006.92	3,578.53	5,627.01	6,614.76
2	Expenses						
	Cost of material consumed	117.46	135.88	162.04	475.93	684.54	837.47
	Employee benefits expense	138.39	128.17	98.03	390.65	236.09	295.86
	Finance costs	23.45	82.02	61.88	166.57	194.34	259.40
	Depreciation and amortization expense	106.34	103.32	97.66	309.42	276.75	374.39
	Fees to hospitals and others	274.39	274.13	290.84	831.63	870.20	1,082.02
	Other expenses	223.95	225.09	240.48	728.91	608.99	811.10
	Total Expenses	883.98	948.61	950.93	2,903.11	2,870.91	3,660.24
3	Profit / (loss) before tax (1) - (2)	222.52	166.32	55.99	675.42	2,756.10	2,954.52
4	Tax expenses						
	Income Tax charge	44.61	28.93	17.75	123.38	48.37	76.47
	Deferred tax charge/(credit)	5.60	12.01	(1.69)	38.29	748.43	1,028.76
	Total tax expenses	50.21	40.94	16.06	161.67	796.80	1,105.23
5	Profit / (loss) for the period/year (3) - (4)	172.31	125.38	39.93	513.75	1,959.30	1,849.29
6	Other comprehensive Income						
	Items that will not be reclassified subsequently to profit and loss						
	Re-measurement gains / (losses) on defined benefit plans	(0.09)	(0.10)	1.30	(0.29)	1.10	(0.38)
	Income tax effect	0.03	0.02	(0.36)	0.07	(0.32)	0.10
	Total other comprehensive Income/(loss) for the period/year	(0.06)	(0.08)	0.94	(0.22)	0.78	(0.28)
7	Total comprehensive Income/(loss) for the period/year, net of tax (5+6)	172.25	125.30	40.87	513.53	1,960.08	1,849.01
8	Paid-up equity share capital (Face Value of Rs. 10/- each as on March 31, 2021 and December 30, 2020 and Rs. 5/ each as on September 30, 2021 and December 31, 2021)	156.99	156.99	51.63	156.99	51.63	64.95
	Instruments entirely equity in nature						2,423.90
	Other equity						(170.20)
	Earnings per share - After Split (Not annualised for quarters & half years)						
	Basic (Rs.)	5.97	4.51	3.87	17.81	189.74	160.36
	Diluted (Rs.)	5.95	4.47	1.55	17.75	6.51	12.25

Place: Pune
Date: January 31, 2022



For & on behalf of Board
Krsnaa Diagnostics Limited

P. Bhatevara

Pallavi Bhatevara
Managing Director
DIN: 03600332

Krsnaa Diagnostics Limited
(Formerly known as Krsnaa Diagnostics Private Limited)

Notes to Unaudited Standalone Financial Results:

1. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on January 31, 2022.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Company is converted from Private Limited Company to Public Limited Company, pursuant to Special Resolution passed in extraordinary general meeting of the shareholders held on April 25, 2021 & consequently the name of the Company has been changed to Krsnaa Diagnostics Limited pursuant to fresh certificate of Incorporation issued by Registrar of Company dated May 6, 2021.
4. The Company, pursuant to shareholders' resolution dated April 25, 2021, sub-divided its equity share capital by sub-dividing the face value of the Equity Shares from ₹10 to ₹5 per Equity Share. Accordingly, the issued and paid-up capital of our Company was sub-divided from 6,494,964 Equity Shares of ₹10 each to 12,989,928 Equity Shares of ₹5 each.
5. Pursuant to resolution passed at the meeting of Board of Director's held on July 23, 2021, 1,42,01,600 equity shares were issued to compulsory convertible preference shareholders of series A and series C in the ratio 2:1
6. The Company has completed Initial Public Offer (IPO) of 1,27,31,605 Equity Shares of the face value of Rs. 5/- each at an issue price of Rs. 954/- per Equity Share to non employee category shareholders and Rs. 861/- per Equity Share to employee category shareholders, comprising offer for sale of 85,25,520 equity shares by selling shareholders and fresh issue of 42,06,085 equity shares. The equity shares of the Company were listed on BSE Limited and National Stock Exchange of India Limited on August 16, 2021. Accordingly, the unaudited standalone financial results for the quarter and six months ended September 30, 2021 were drawn up for the first time in accordance with the Listing Requirements. Thus, unaudited standalone financial results for the quarter ended December 31, 2020 have not been subject to an audit or review by the statutory auditors of the Company. Further, the unaudited standalone financial information for the nine months ended December 31, 2020 were audited, on which special purpose audit report dated May 13, 2021 with an unmodified opinion was issued by the statutory auditors of the Company for the purpose of inclusion in the offer document and the financial results for the nine months ended December 31, 2020 have been prepared accordingly.
7. The company has invested into seven special purpose vehicles (SPVs) which are wholly owned subsidiaries namely, - KDPL Diagnostics (Ludhiana) Private Limited on March 22, 2021, KDPL Diagnostics (Amritsar) Private Limited on March 24, 2021, KDPL Diagnostics (Bathinda) Private Limited on March 24, 2021, KDPL Diagnostics (Jalandhar) Private Limited on March 24, 2021, KDPL Diagnostics (Patiala) Private Limited on March 25, 2021, KDPL Diagnostics (SAS Nagar) Private Limited on March 25, 2021 and Krsnaa Diagnostics (Mohali) Private Limited on July 27, 2021
The company has remitted the amount towards subscription of share capital in these SPVs on April 12, 2021 & August 21, 2021.
8. The Company's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, Tele- Reporting Services, and all type of Blood and Urine Investigation. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence no separate segment information has been furnished herewith.
- 9.. The management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the quarter & nine months ended December 31, 2021 and has concluded that the impact is primarily on the operational aspects of the business. In making the assessment management has considered the recoverability of trade receivables, investment and other assets and also considered the external and internal information available up to the date of approval of these financial results including status of existing and future customer orders, cash flow projections etc. and concluded that there is no significant impact which is required to be recognized in the financial results. Accordingly, no adjustments have been made to the financial results.
10. Previous period figures have been regrouped/ rearranged wherever considered necessary.

For & on behalf of Board
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: January 31, 2022

